MX2009004792A - Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. - Google Patents

Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Info

Publication number
MX2009004792A
MX2009004792A MX2009004792A MX2009004792A MX2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A
Authority
MX
Mexico
Prior art keywords
pai
treatment
binding
glaucoma
compound
Prior art date
Application number
MX2009004792A
Other languages
English (en)
Spanish (es)
Inventor
Iok-Hou Pang
Debra Fleenor
Abbot Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2009004792A publication Critical patent/MX2009004792A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009004792A 2006-10-31 2007-10-31 Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. MX2009004792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31
PCT/US2007/083170 WO2008055205A2 (en) 2006-10-31 2007-10-31 Pai-1 binding modulators for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MX2009004792A true MX2009004792A (es) 2009-05-21

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004792A MX2009004792A (es) 2006-10-31 2007-10-31 Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Country Status (11)

Country Link
US (2) US20080107644A1 (enExample)
EP (1) EP2077829A2 (enExample)
JP (1) JP2010508306A (enExample)
KR (1) KR20090082401A (enExample)
CN (1) CN101588798A (enExample)
AU (1) AU2007313684A1 (enExample)
CA (1) CA2666316A1 (enExample)
MX (1) MX2009004792A (enExample)
RU (1) RU2465898C2 (enExample)
WO (1) WO2008055205A2 (enExample)
ZA (1) ZA200902453B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
EP2790023B1 (en) 2011-11-15 2018-07-04 National University Corporation Hamamatsu University School of Medicine Therapeutic and diagnostic agent for early delivery or abortion using plasminogen activator inhibitor-1
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024121A1 (fr) * 1992-05-22 1993-12-09 Senju Pharmaceutical Co., Ltd. Medicament pour le glaucome
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO2000035439A1 (en) * 1998-12-11 2000-06-22 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제

Also Published As

Publication number Publication date
EP2077829A2 (en) 2009-07-15
CA2666316A1 (en) 2008-05-08
ZA200902453B (en) 2010-07-28
WO2008055205A2 (en) 2008-05-08
CN101588798A (zh) 2009-11-25
JP2010508306A (ja) 2010-03-18
WO2008055205A3 (en) 2008-07-17
US20080107644A1 (en) 2008-05-08
AU2007313684A1 (en) 2008-05-08
KR20090082401A (ko) 2009-07-30
US20100260784A1 (en) 2010-10-14
RU2465898C2 (ru) 2012-11-10
RU2009120545A (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
WO2007022470A3 (en) Methods and compositions for treating neurological disease
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
MX2009010854A (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EP2340258A4 (en) PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
UA94953C2 (en) Ep2 agonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal